Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Sumitomo Pharma America, Inc.
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Subject is judged by the investigator to be suitable for participation in a 24-week clinical trial involving open-label lurasidone treatment
Subject has completed the 6-week treatment period and all required assessments on the final study visit (Day 42, Visit 8) of either Study D1050235, NCT#00868452 or Study D1050236, NCT#008668699.
You may not be if
Imminent risk of suicide, injury to self or to others, or damage to property
Subject has evidence of severe movement disorders.
Subject tests positive for drugs of abuse (at Visit 8 in Study D1050235, NCT#00868452 or D1050236, NCT#008688699).
Clareo Health | Lurasidone - A 24-week Extension Study of Patients With Bipolar I Depression
